• NEWS & PUBLICATIONS
  • News and Media
  • Newsletters
  • Journals
  • Books
• MEMBERSHIP
  • Join/Renew
  • Benefits
  • Categories
  • Download a Member Application
  • Grants, Awards, and Scholarships
  • Access the Phantom Analysis Toolkit
  • Membership Directory
  • Chapters
  • Centers of Excellence
  • Councils
  • Member Spotlight
  • Women in Nuclear Medicine
  • SNMMI Fellow
  • SNMMI-TS Fellow
  • Council and Center Internships
• EDUCATION
  • Learning Center
  • 2023 MWM/ACNM Call for Abstracts
  • Webinars
• MEETINGS & EVENTS
  • Calendar of Events
  • Webinars
  • 2022 Fall Therapeutics Conference
  • FDA Quantitative PET Amyloid Imaging Workshop
  • 2023 Mid-Winter Meeting
  • 2023 MWM/ACNM Call for Abstracts
  • 2023 Annual Meeting
  • Nuclear Medicine & Molecular Imaging Week
  • SNMMI-TS Leadership Academy
  • SNMMI Future Leaders Academy
• ADVOCACY
  • Coding & Reimbursement
  • Legislative Efforts
  • Government Relations News
  • Radiopharmaceutical Supply News
  • USP 825
  • Technologist State Issues
  • Position Statements
  • FDA PET Drug Manufacturing Q&A
• EVIDENCE & QUALITY
  • Clinical Guidelines and AUC
  • Quality
  • Practice Resources
  • Dose Optimization
  • About Quality & Practice
  • Dosimetry
• RESEARCH
  • Clinical Trials Network
  • Radiopharmaceutical Therapy Central
  • Radiopharmaceutical Therapy Centers of Excellence
  • Preclinical Imaging
  • Nuclear Medicine Clinical Trial Group, LLC
  • Research: Learn More
• ABOUT SNMMI
  • Strategic Plan
  • Bylaws & Procedures
  • Governance - SNMMI
  • Governance - SNMMI-TS
  • History
  • Grants, Awards, and Scholarships
  • Career Center
  • About Nuclear Medicine & Molecular Imaging
  • International Collaboration
  • Outreach
  • Support SNMMI
  • Contact Us

Press Release

• Novel PET Agent Effectively Detects Multiple Cancers, Identifies Patients for Targeted Therapies

  Nov 17, 2022 — A new molecular imaging radiotracer, Ga-68 PentixaFor, can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies.

• PET/MRI Machine Learning Model Can Eliminate Sentinel Lymph Node Biopsy in Majority of Breast Cancer Patients

  Nov 10, 2022 — Nearly 70 percent of breast cancer patients could find out if their cancer has spread to their lymph nodes without having to undergo an invasive sentinel node biopsy, according to new research published in JNM.

• CTN: Enabling Accurate Quantitative PET/CT and SPECT/CT Imaging

  Oct 25, 2022 — Quantitative measurements have long been a strength of nuclear medicine. There is renewed urgency for accurate, reproducible, and standardized measurements in routine clinical practice as the role of diagnostic and therapeutic radiopharmaceuticals in clinical trials and routine clinical care grows. The CTN continues to be involved in this space, with several active projects to address this need.

• Novel PET Imaging Agent Detects Earliest Signs of Alzheimer’s Disease

  Oct 19, 2022 — A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B (MAO-B) in cognitively unimpaired individuals with high beta amyloid, according to research published in the October issue of JNM.

• Ultra-Low Dose Total Body PET/CT Effective for Evaluating Arthritis

  Oct 12, 2022 — Total body PET/CT scans can successfully visualize systemic joint involvement in patients with autoimmune arthritis, according to new first-in-human research published in the October issue of JNM.

• SNMMI and the Lobular Breast Cancer Alliance Announce $100,000 Research Grant

  Oct 3, 2022 — SNMMI announces a new $100,000 grant to fund research on nuclear medicine imaging and treatments for lobular beast cancer. The grant is sponsored by the SNMMI Mars Shot Fund and the Lobular Breast Cancer Alliance.

• New PET Tracer Shows Promise for uPAR-Targeted Therapy of Neuroendocrine Neoplasms

  Sep 28, 2022 — A novel PET radiotracer can accurately assess the presence of a biomarker that indicates the level of tumor aggressiveness in neuroendocrine neoplasms, according to research published in September JNM, and may also serve as a potential target for peptide radionuclide therapy (PRRT) for NEN patients.

• TerraPower Announces Funding Raised for Nuclear Technologies

  Sep 20, 2022 — TerraPower, a nuclear innovation company founded by Bill Gates, announced a $750 million funding raise co-led by Gates and SK, a large South Korean conglomerate that is one of South Korea’s largest energy providers. According to a press release from TerraPower, this effort will enhance the company’s “groundbreaking work in advanced nuclear energy technologies and nuclear medicine.”

• SNMMI PR Campaign Lands Stories in Major Media Markets

  Sep 12, 2022 — SNMMI’s consumer-focused public relations initiative to raise awareness about what nuclear medicine is and what it can accomplish has seen continued success in the summer months.

• A Special Issue of the Journal of Nuclear Medicine Technology Highlights the New Frontier of Theranostics

  Sep 12, 2022 — A special issue of the Journal of Nuclear Medicine Technology focuses on theranostics as it relates to technologists and includes articles on quality and practice management, imaging, and radiation safety, as well as continuing education articles.

• New Research Shows PSMA PET/CT Imaging Changes Management for Close to 50 Percent of Prostate Cancer Patients

  Sep 7, 2022 — In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with 18F-DCFPyL PSMA PET/CT has been shown to considerably improve detection of active disease as compared to imaging with CT alone.

• Francoeur to Lead Patient Advocacy Advisory Board for Society of Nuclear Medicine and Molecular Imaging

  Aug 11, 2022 — Jeri Francoeur of Ormond Beach, Florida, has been elected to a two-year term as chair of SNMMI's Patient Advocacy Advisory Board.

• Crosby Elected Vice Chair of Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging

  Aug 11, 2022 — Mike Crosby of San Diego, California, has been elected to a two-year term as vice chair of SNMMI's Patient Advocacy Advisory Board.

• Journal of Nuclear Medicine Impact Factor Rises Again

  Jun 29, 2022 — The Journal of Nuclear Medicine has again achieved the highest impact factor in its history, ranking fourth among all medical imaging journals worldwide, according to new data just released in Clarivate's 2021 Journal Citation Reports.

• Revolutionary Technology Shortens Cardiac Scan Time, Provides High-Quality SPECT Images

  Jun 14, 2022 — A cardiac SPECT imaging system performs scans 10 to 100 times faster than current SPECT systems, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• PSMA PET Highlights Need for Updated Prostate Cancer Therapy Guidelines

  Jun 14, 2022 — Current guidelines used to plan salvage radiation treatments in patients with local recurrence of prostate cancer should be updated to take into consideration information derived from novel imaging modalities, such as PSMA PET.

• Novel Radiopharmaceutical Pair Detects and Treats Melanoma; Study Shows Potential for Broad Application in Solid Tumors

  Jun 14, 2022 — A newly developed small-molecular radiopharmaceutical pair has successfully visualized and treated melanoma in a preclinical study, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• SNMMI Image of the Year: New Biomarker Predicts Severity of Cardiac Remodeling after Heart Attack

  Jun 14, 2022 — Poor functional outcomes after a heart attack can be predicted with a new PET imaging agent, Ga-68-FAPI-46. The detailed depiction of Ga-68-FAPI-46 PET signal after acute anterior myocardial infarction has been selected as SNMMI’s 2022 Image of the Year.

• SNNMI Abstract of the Year: Targeted Radionuclide Treatment Achieves High Response Rate, Minimal Toxicities for Advanced-Stage Neuroendocrine Tumors

  Jun 14, 2022 — A targeted radionuclide alpha therapy, Ac-225 DOTATATE, has been shown to have long-term anti-tumor effects in patients with advanced-stage gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

• SNMMI Elects Cathy Sue Cutler, PhD, FSNMMI, as Vice President-Elect at 2022 Annual Meeting

  Jun 13, 2022 — Cathy Sue Cutler, PhD, FSNMMI, director of the medical isotope research and production program at Brookhaven National Laboratory in Upton, New York, has been named as vice president-elect for the Society of Nuclear Medicine and Molecular Imaging.

• Andrei Iagaru, MD, FACNM, Receives Inaugural SNMMI Sam Gambhir Trailblazer Award

  Jun 13, 2022 — Andrei Iagaru, MD, FACNM, professor of radiology (nuclear medicine) and chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University, in Stanford, California, has been named as the first recipient of the Sam Gambhir Trailblazer Award.

• SNMMI Elects Munir Ghesani, MD, FACNM, FACR, as President at 2022 Annual Meeting

  Jun 12, 2022 — Munir Ghesani, MD, FACNM, FACR, chief of nuclear medicine and molecular imaging at Mount Sinai Health System and associate professor of radiology at Mount Sinai Hospital in New York, NY, has been named as president for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

• SNMMI Announces Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, as President of the Technologist Section During 2022 Annual Meeting

  Jun 13, 2022 — Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, instructor and clinical coordinator at the University of Alabama at Birmingham in Birmingham, Alabama, has been elected as the 2022-23 president for the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS).

• SNMMI Announces Dmitry Beyder, CNMT, MPA, as President-Elect of the Technologist Section During 2022 Annual Meeting

  Jun 13, 2022 — Dmitry Beyder, CNMT, MPA, radiology program manager of nuclear medicine, PET, CT and patient transport at Barnes-Jewish Hospital/Mallinckrodt Institute of Radiology in St. Louis, Missouri, has been elected as the 2022-23 president-elect for the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS).

• SNMMI Launches Mars Shot Fund for Nuclear Medicine Research; Initial Donations Top $600,000

  Jun 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) today announced the creation of the Mars Shot Fund, an initiative to raise $100 million to help pay for research into nuclear medicine, molecular imaging, and therapy.

• Society of Nuclear Medicine and Molecular Imaging Announces 2022 Fellows

  Jun 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging recognized 15 new SNMMI Fellows on Monday, June 13, during a plenary session at the society’s 2022 Annual Meeting.

• Simon R. Cherry, PhD, Receives 2022 Benedict Cassen Prize for Research in Molecular Imaging

  Jun 13, 2022 — Simon R. Cherry, PhD, known for his pioneering work in the development of PET technology and co-development of the EXPLORER total-body PET/CT scanner, was awarded the Benedict Cassen Prize during the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• Virtual CT Scans Cut Patient Radiation Exposure in Half During PET/CT Studies

  Jun 12, 2022 — A novel artificial intelligence method can be used to generate high-quality “PET/CT” images and subsequently decrease radiation exposure to the patient.

• Molecular Imaging Biomarker Predicts Response to CAR T Cell Therapy

  Jun 12, 2022 — A new PET imaging agent, F-18 AlF-FAPI-74, has been found to effectively monitor and predict treatment response of CAR T cell therapy. This non-invasive imaging approach has the potential to help inform important clinical decision-making early in the course of treatment—including re-dosing of therapy, dose optimization, change of therapeutic course, and many more—to optimize patient outcomes.

• Markus Schwaiger, MD, Receives SNMMI Georg Charles de Hevesy Nuclear Pioneer Award

  Jun 12, 2022 — Markus Schwaiger, MD, a scientist known for his contributions to cardiac PET imaging, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.

• Robert H. Mach, Phd, Receives SNMMI 2022 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science

  Jun 12, 2022 — Robert H. Mach, PhD, has been named the 2022 recipient of the prestigious Paul C. Aebersold Award.

• PET/CT Effective in Evaluating and Monitoring Post-COVID-19 Lung Disease

  Jun 11, 2022 — F-18 FDG PET/CT has been proven successful in evaluating lung inflammation and monitoring treatment effects in patients suffering from post-COVID-19 lung disease.

• PET Imaging Confirms Link Between Obstructive Sleep Apnea and Heart Blood Flow Impairment

  Jun 11, 2022 — Patients with severe obstructive sleep apnea (OSA) are less able to increase blood flow to the heart when needed, according to a first-of-its-kind PET imaging study presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• New Targeted Radionuclide Alpha Therapy Improves Prostate Cancer Outcomes

  Jun 11, 2022 — A novel targeted radionuclide alpha therapy for metastatic castration-resistant prostate cancer—225AC-NM600—has been shown to achieve significantly better outcomes than its corresponding targeted radionuclide beta therapy.

• Novel Ultra-Low Dose PET Technique Significantly Reduces Radiation Exposure

  Jun 11, 2022 — A new PET imaging technique can greatly reduce the amount of patient radiation exposure by eliminating the need for an accompanying CT scan. Without the CT scan, the amount of radiation delivered to the patient is cut dramatically, which benefits all patients, but in particular the pediatric population and those in need of multiple scans.

• Novel PET Agent Highly Effective for Imaging Meningiomas; Offers Logistical Advantages Over Standard Agents

  Jun 11, 2022 — A novel somatostatin-receptor (SSTR) targeting peptide—18F-SiTATE—has been shown to provide excellent imaging in patients with meningiomas, identifying bone involvement and lesions previously undetected on standard morphological imaging.

• Active Brown Adipose Tissue Protects Against “Pre-Prediabetes”

  May 4, 2022 — In a prospective study of young, lean adults, PET/CT imaging revealed that higher levels of active brown adipose tissue (also known as “brown fat”) are more prevalent in individuals who exhibit very early indications of metabolic disorders. The research was published ahead of print in The Journal of Nuclear Medicine.

• JNM Publishes Joint Guide for the Establishment of Theranostics Centers

  Apr 29, 2022 — SNMMI, the European Association of Nuclear Medicine, and the International Atomic Energy Agency have created a new guide for the creation of dedicated theranostics centers.

• Novel Deep Learning Method Provides Early and Accurate Differential Diagnosis for Parkinsonian Diseases

  Apr 21, 2022 — A new deep learning method has been created to aid in the diagnosis of parkinsonian diseases, according to research published in JNM.

• New ASNC/SNMMI Training Course Helps Physicians Meet U.S. Requirements for Handling Medical Radioisotopes

  Apr 12, 2022 — SNMMI and ASNC have released a new “80 Hour Radionuclide Authorized User Training Course” for nuclear medicine physicians, which will fulfill the 80 hours of classroom training required by the NRC and Agreement States for physicians to become Authorized Users.

• SNMMI Releases Statement on CMS Final Decision for Alzheimer’s Disease Coverage

  Apr 8, 2022 — CMS has announced its final decision on coverage of monoclonal antibodies to treat Alzheimer’s disease. It includes no additional coverage for beta amyloid PET scans, which will continue to be limited to one per patient per lifetime.

• New Radionuclide Combination Therapy Safe and Effective in Metastatic Prostate Cancer Patients

  Apr 7, 2022 — A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre-treated metastatic castration-resistant prostate cancer. The research was published in the April issue of JNM.

• SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment

  Mar 23, 2022 — SNMMI applauds the FDA's approval of a new, game-changing nuclear medicine treatment for metastatic prostate cancer shown to reduce risk of death by 38% and risk of progression by 60% in mCRPC patients.

• Molecular Imaging Uncovers Effects of COVID-19 on the Brain

  Mar 15, 2022 — A significant number of COVID-19 neurological complications—such as fatigue, headache, and cognitive impairment—are ultimately reversible, according to new research in The Journal of Nuclear Medicine.

• SNMMI Designates First Radiopharmaceutical Therapy Centers of Excellence

  Mar 10, 2022 — SNMMI has named Stanford Health Care and the Dana-Farber Brigham Cancer Center as its first two designated Radiopharmaceutical Therapy Centers of Excellence.

• Novel Radioligand Therapy Proven Superior for Metastatic Prostate Cancer Patients

  Mar 9, 2022 — A novel prostate cancer treatment—Ac-225 PSMA-617 radioligand therapy—has been shown to increase the progression free survival and overall survival of metastatic castration-resistant prostate cancer patients, according to research published by JNM.

• SNMMI Launches New Quality Systems Personnel Training Program

  Jan 31, 2022 — SNMMI has launched the Quality Systems Personnel Training Program (QSPTP) to educate, train, and develop individuals with a pharmacy or chemistry background in the production and release of clinical radiopharmaceuticals.

• PSMA PET Validates EAU Classification System to Determine Risk of Prostate Cancer Recurrence

  Jan 20, 2022 — Research published in the January issue of JNM has confirmed the accuracy of the European Association of Urology risk classification system that groups prostate cancer patients based on their risk of recurrence.

• SNMMI Reacts to CMS Coverage Decision on New Alzheimer’s Therapy

  Jan 12, 2022 — On January 11, CMS announced that it proposes to cover FDA-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease under CED in CMS-approved randomized controlled trials. SNMMI reacts.

• PET/CT Artificial Intelligence Model Ideal for Predicting Risk of Future Heart Attack

  Jan 11, 2022 — When assessed together in an AI model, coronary F-18 NaF uptake on PET and quantitative coronary plaque characteristics on CT angiography were found to provide risk prediction superior to that of clinical data alone.

• JNM Publishes Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging

  Jan 7, 2022 — SNMMI and peer medical groups have issued AUC for PSMA PET imaging. Published in the January issue of JNM, the criteria are the product of an international multidisciplinary panel of expert healthcare providers.

• Senate Passes Protecting Medicare and American Farmers from Sequester Cuts Act

  Dec 10, 2021 — Last night, SNMMI and more than 300 medical societies rejoiced when the Senate passed the Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610).

• Novel Radionuclide Therapy Proven Safe and Effective to Treat Neuroendocrine Neoplasms

  Nov 19, 2021 — A new type of PRRT has been shown to control disease in 85 percent of patients with metastatic neuroendocrine neoplasms, achieving complete remission in some patients, according to research published in JNM.

• SNMMI Adopts Family Leave Statement

  Nov 12, 2021 — SNMMI’s Women in Nuclear Medicine Committee, Nuclear Medicine Program Directors Committee, and Diversity, Equity and Inclusion Task Force collaborated to create an SNMMI Family Leave Statement, which was adopted by the SNMMI Board of Directors on November 1, 2021.

• Molecular Imaging Suggests Long-COVID Symptoms May Be Caused by Fatigue, Not Regional Brain Dysfunction

  Oct 29, 2021 — Long-term cognitive problems after a COVID-19 diagnosis may be a result of fatigue rather than pathological changes in the brain, according to a study published ahead-of-print in JNM.

• SNMMI 2021-2023 Wagner-Torizuka Fellowship Recipient Announced

  Oct 15, 2021 — SNMMI is pleased to announce the recipient of the 2021-2023 SNMMI Wagner-Torizuka Fellowship. This two-year fellowship, founded in 2008 by the late Henry N. Wagner, Jr., MD, and the late Kanji Torizuka, MD, PhD, is designed to provide extensive training and experience in the fields of nuclear medicine and molecular imaging for Japanese physicians in the early stages of their careers. Applications are available for 2022-2024 fellowships.

• PSMA PET Imaging More Accurate Than CT in Detecting Hepatocellular Carcinoma

  Sep 30, 2021 — PSMA PET/CT is more accurate than conventional CT in the detection of hepatocellular carcinoma metastases and was associated with a change of management for nearly half of patients, according to research published in the September issue of The Journal of Nuclear Medicine.

• Newly Approved PET Imaging Agent Solves Clinical Dilemmas in Breast Cancer Patients

  Sep 29, 2021 — A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for breast cancer patients when diagnostic dilemmas arise, according to research published in the September issue of The Journal of Nuclear Medicine.

• New Radionuclide Therapy Identified for HER2-Positive Breast Cancer Patients

  Sep 28, 2021 — A promising radionuclide treatment may offer new therapeutic options for breast cancer patients, according to research published in The Journal of Nuclear Medicine.

• Topical Molecular Imaging Tracer Enables Real-Time Detection of Cervical Cancer

  Jul 27, 2021 — With the help of a topical fluorescent imaging agent, cervical cancer can be identified by physicians with a hand-held microscope, according to research published in the July issue of JNM.

• Novel Imaging Agent Identifies Biomarker for Iron-Targeted Cancer Therapies

  Jul 22, 2021 — A new radiotracer that detects iron in cancer cells has proven effective, opening the door for the advancement of iron-targeted therapies for cancer patients.

• Total-Body PET Imaging Exceeds Industry Standards

  Jul 7, 2021 — A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high sensitivity that supports excellent spatial resolution and image quality, according to research published in The Journal of Nuclear Medicine.

• Molecular Imaging Improves Staging and Treatment of Pancreatic Ductal Adenocarcinomas

  Jul 5, 2021 — For patients with pancreatic ductal adenocarcinomas, molecular imaging can improve staging and clinical management of the disease, according to research published in JNM.

• Journal of Nuclear Medicine Impact Factor Surges More than 27%

  Jul 1, 2021 — The Journal of Nuclear Medicine has again achieved the highest impact factor ever in its history, now ranking third among all medical imaging journals worldwide, according to new data just released in the 2020 Journal Citation Reports.

• SNMMI Announces Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, as President-Elect of the Technologist Section During 2021 Annual Meeting

  Jun 15, 2021 — Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, has been elected as the 2021-22 president-elect for the SNMMI-TS.

• SNMMI Announces Dusty M. York, MAEd, CNMT, PET, ARRT(N)(CT) as President of the Technologist Section During 2021 Annual Meeting

  Jun 15, 2021 — Dusty M. York, MAEd, CNMT, PET, ARRT(N)(CT), has been elected as the 2021-22 president for the SNMMI-TS.

• PSMA-Targeted Radiotracer Pinpoints Metastatic Prostate Cancer Across Anatomic Regions

  Jun 15, 2021 — A phase III clinical trial has validated the effectiveness of the PSMA-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer. This study was presented at the SNMMI 2021 Annual Meeting.

• SNMMI Image of the Year: PET Imaging Measures Cognitive Impairment in COVID-19 Patients

  Jun 15, 2021 — The effects of COVID-19 on the brain can be accurately measured with positron emission tomography (PET), according to research presented at the SNMMI 2021 Annual Meeting. The detailed depiction of areas of cognitive impairment, neurological symptoms and comparison of impairment over a six-month time frame has been selected as SNMMI’s 2021 Image of the Year.

• Novel Radiotracer Shows Promise to Predict Abdominal Aortic Aneurysm Rupture

  Jun 15, 2021 — A new PET radiotracer can detect abdominal aortic aneurysms and potentially predict when they will rupture, according to research presented at the SNMMI 2021 Annual Meeting.

• SNMMI Elects Helen Nadel, MD, FRCPC, as Vice President-Elect at 2021 Annual Meeting

  Jun 14, 2021 — Helen Nadel, MD, FRCPC, has been named as SNMMI vice president-elect. SNMMI introduced a new slate of officers during its 2021 Virtual Annual Meeting, held June 11-15.

• SNMMI Elects Munir Ghesani, MD, FACNM, FACR, as President-Elect at 2021 Annual Meeting

  Jun 14, 2021 — Munir Ghesani, MD, FACNM, FACR, has been named as SNMMI president-elect. SNMMI introduced a new slate of officers during its 2021 Virtual Annual Meeting, held June 11-15.

• Society of Nuclear Medicine and Molecular Imaging Announces 2021 Fellows

  Jun 14, 2021 — SNMMI recognized 17 new SNMMI Fellows on Monday, June 14, during a plenary session at the society’s 2021 Annual Meeting, held virtually June 11-15.

• Steven M. Larson, MD, Receives SNMMI 2021 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science

  Jun 14, 2021 — Steven M. Larson, MD, has been named the 2021 recipient of the prestigious Paul C. Aebersold Award. The award was announced by the SNMMI during its 2021 Annual Meeting.

• SNMMI Elects Richard L. Wahl, MD, as President During 2021 Annual Meeting

  Jun 14, 2021 — Richard L. Wahl, MD, has been elected 2021-22 president of the Society of Nuclear Medicine and Molecular Imaging. SNMMI introduced a new slate of officers during its 2021 Virtual Annual Meeting, held June 11-15.

• New PET Tracer Detects Hallmark of Alzheimer’s Disease Years Before Symptoms Emerge

  Jun 14, 2021 — A novel PET radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed. The research was presented at the SNMMI 2021 Annual Meeting.

• Lipophilic Statin Use Linked to Increased Risk of Dementia

  Jun 14, 2021 — In patients with mild cognitive impairment, taking lipophilic statins more than doubles their risk of developing dementia compared to those who do not take statins. According to research presented at the SNMMI 2021 Annual Meeting, PET scans of lipophilic statin users revealed a highly significant decline in metabolism in the area of the brain that is first impacted by Alzheimer’s disease.

• New Theranostic Approach Combines Radiopharmaceuticals and Nanoparticles to Kill Cancer Cells

  Jun 14, 2021 — Researchers have successfully developed a novel cancer treatment approach that utilizes Cerenkov radiation energy to target and destroy cancer cells more effectively, according to new research presented at SNMMI’s 2021 Virtual Annual Meeting.

• Novel Radiopharmaceutical Tracks “Master Switch” Protein Responsible for Cancer Growth

  Jun 14, 2021 — A protein that is critical in cancer cell metabolism has been imaged for the first time with a newly developed radiopharmaceutical, 18F-DASA-23, according to research presented at the SNMMI 2021 Annual Meeting.

• Deep Learning with SPECT Accurately Predicts Major Adverse Cardiac Events

  Jun 13, 2021 — Deep learning can predict major adverse cardiac events more accurately than current standard imaging protocols, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.

• Thomas J. Ruth, PhD, FRSC, FSRS, Receives SNMMI Georg Charles de Hevesy Nuclear Pioneer Award

  Jun 13, 2021 — Thomas J. Ruth, PhD, FRSC, FSRS, a scientist known for his contributions to nuclear medicine and nuclear chemistry, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.

• New Super-Resolution Technique Allows for More Detailed Brain Imaging

  Jun 13, 2021 — A new imaging technique termed "super-resolution" has the potential to detect neurological disorders—such as Alzheimer’s disease—at their earliest stages, enabling physicians to diagnose and treat patients more quickly.

• PET Radiotracer Effective for Detection and Assessment of Lung Fibrosis

  Jun 13, 2021 — PET using a Ga-68–labeled fibroblast activation protein inhibitor (FAPI) can noninvasively identify and monitor pulmonary fibrosis, according to research presented at the SNMMI 2021 Annual Meeting.

• Promising Ovarian Cancer Treatment Proves Effective and Efficient

  Jun 12, 2021 — Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass.

• With Advent of New Treatments, PET Imaging Adds Valuable Information to Brain Metastasis Monitoring

  May 3, 2021 — For patients with brain metastases, amino acid PET can provide valuable information about the effectiveness of state-of-the-art treatments.

• New Radiotracer Safe and Effective for Imaging Early Rheumatoid Arthritis

  Apr 15, 2021 — New research shows that a novel PET tracer that targets inflammation is safe and can clearly identify early stages of rheumatoid arthritis.

• New Treatment Proves More Effective and Less Toxic for Neuroendocrine Tumor Patients

  Mar 19, 2021 — A new treatment for late-stage neuroendocrine tumors has been found to be more effective and have fewer side effects than the current standard of care, according to research published in JNM.

• Immuno-PET Can Give Physicians Early Insight into Tumor Response to Targeted Therapy

  Mar 12, 2021 — Immuno-PET imaging can provide early insight into a tumor’s response to targeted therapy, allowing physicians to select the most effective treatment for patients who have cancer.

• Molecular Imaging Determines Effectiveness of Novel Metastatic Breast Cancer Treatment

  Feb 16, 2021 — Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy, according to research published in the February issue of JNM.

• Joint Radionuclide Therapy-Immunotherapy Approach Effective in Prostate Cancer Model

  Feb 6, 2021 — A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of JNM.

• Expanded PET Imaging Time Window Adds Convenience and Flexibility for Neuroendocrine Tumor Patients

  Jan 20, 2021 — The imaging time window of 64Cu-DOTATATE positron emission tomography/computed tomography (PET/CT) for patients with neuroendocrine neoplasms can be expanded from 1 hour to 3 hours post-injection, according to new research published in JNM.

• Potential Jurors Favor Use of Artificial Intelligence in Precision Medicine

  Jan 11, 2021 — Physicians who follow artificial intelligence advice may be considered less liable for medical malpractice than is commonly thought, according to a new study published in JNM.

• New Theranostic Approach Reduces Tumor Volume and Increases Survival in Neuroendocrine Tumor Study

  Dec 15, 2020 — A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival, according to new research published in JNM.

• PET Imaging Tracer Proves Effective for Diagnosing and Managing Rare CNS B-Cell Lymphoma

  Dec 9, 2020 — PET imaging with Ga-68-pentixafor is an effective diagnostic tool for central nervous system B-cell lymphoma, according to a proof-of-concept study published in the December issue of JNM.

• The Journal of Nuclear Medicine Celebrates 60 Years of Research

  Dec 9, 2020 — The Journal of Nuclear Medicine (JNM) has issued a special supplement commemorating six decades of leadership in the field of nuclear medicine, molecular imaging and therapy.

• FDA Announces First-Ever Approval of PSMA PET for Prostate Cancer Imaging

  Dec 2, 2020 — The FDA has approved ga-68 PSMA-11 for PET imaging of PSMA–positive lesions in men with prostate cancer. It is the first approval for a PSMA PET drug in the United States.

• Multi-Center, Multi-Tracer PET Studies Harmonized to Detect Neuroinflammation in ALS

  Dec 1, 2020 — A novel ALS (amyotrophic lateral sclerosis) study has pooled data from multiple sites to effectively visualize neuroinflammation, which is key to developing drugs to treat the disease.

• Novel Therapy Approach for Hyperinsulinemic Hypoglycemia

  Nov 6, 2020 — A new method to treat hyperinsulinemic hypoglycemia has proved highly selective in targeting lesions and effective in slowing tumor growth, according to research published in the November issue of JNM.

• Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug

  Oct 7, 2020 — A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research featured in the October issue of JNM.

• Cerenkov Luminescence Imaging Accurately Identifies Surgical Margin Status During Radical Prostatectomy

  Oct 6, 2020 — A new intraoperative imaging technique, Cerenkov luminescence imaging, can accurately assess surgical margins during radical prostatectomy, according to a first-in-human research published in the October issue of JNM.

• SNMMI 2020-2022 Wagner-Torizuka Fellowship Recipients Announced

  Sep 8, 2020 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased to announce the recipients of the 2020-2022 SNMMI Wagner-Torizuka Fellowship.

• Updated Statement: COVID-19 and Ventilation/Perfusion (V/Q) Lung Studies

  Sep 3, 2020 — SNMMI has released an updated statement on COVID-19 and ventilation/perfusion (V/Q) lung studies.

• Virtual Patient Education Day Event Draws 600+ Viewers

  Aug 28, 2020 — SNMMI and its Patient Advocacy Advisory Board (PAAB) held the Society’s annual Patient Education Day this year as a series of three virtual sessions, reaching the highest number of patients in the event’s nine-year history.

• A Virtual Celebration of Life for Sam Gambhir, MD, PhD to take place on Friday, August 14, 2020

  Aug 8, 2020 — A Virtual Celebration of Life will take place on Friday, August 14, 2020 to honor molecular imaging pioneer Sanjiv “Sam” Gambhir, MD, PhD, who passed away on Saturday, July 18, from cancer.

• Molecular Imaging Pioneer Sam Gambhir Passes Away

  Jul 19, 2020 — Molecular imaging pioneer Sanjiv “Sam” Gambhir, MD, PhD, passed away on Saturday, July 18, from cancer.

• SNMMI Announces Tina M. Buehner, MS, CNMT, NMTCB(CT)(RS), RT(N)(CT), FSNMMI-TS, as President of Technologist Section during 2020 Annual Meeting

  Jul 14, 2020 — Tina M. Buehner, MS, CNMT, NMTCB(CT)(RS), RT(N)(CT), FSNMMI-TS, has been named 2020-21 president of the Society of Nuclear Medicine and Molecular Imaging Technologist Section.

• SNMMI Announces Dusty M. York, MAEd, CNMT, PET, ARRT(N)(CT) as President-Elect of the Technologist Section During 2020 Annual Meeting

  Jul 14, 2020 — Dusty M. York, MAEd, CNMT, PET, ARRT(N)(CT), has been elected as the 2020-21 president-elect for the Society of Nuclear Medicine and Molecular Imaging Technologist Section.

• SNMMI Elects Richard L. Wahl, MD, as President-Elect During 2020 Annual Meeting

  Jul 13, 2020 — Richard L. Wahl, MD, has been elected 2020-21 president-elect of the Society of Nuclear Medicine and Molecular Imaging.

• SNMMI Elects Alan B. Packard, PhD, as President During 2020 Annual Meeting

  Jul 13, 2020 — Alan Packard, PhD, has been elected 2020-21 president of the Society of Nuclear Medicine and Molecular Imaging.

• Society of Nuclear Medicine and Molecular Imaging Announces 2020 Fellows

  Jul 13, 2020 — The Society of Nuclear Medicine and Molecular Imaging recognized 10 new SNMMI Fellows on Monday, July 13, during a plenary session at the society’s 2020 Annual Meeting.

• SNMMI Elects Munir Ghesani, MD, FACNM, FACR, as Vice President-Elect During 2020 Annual Meeting

  Jul 13, 2020 — Munir Ghesani, MD, FACNM, FACR, has been named as vice president-elect for the Society of Nuclear Medicine and Molecular Imaging.

• Novel Bone Imaging Approach Provides Insights into the Progression of Knee Osteoarthritis

  Jul 12, 2020 — A new approach to functional bone imaging has established that bone metabolism is abnormally elevated in patients with knee osteoarthritis.

• Total-Body Dynamic PET Successfully Detects Metastatic Cancer; First Patient Results Reported

  Jul 12, 2020 — Results from the first study using uEXPLORER to conduct total-body dynamic positron emission tomography (PET) scans in cancer patients show that it can be used to generate high-quality images of metastatic cancer.

• In Recurrent Prostate Cancer, PSMA PET/CT Changes Management in Two-Thirds of Cases

  Jul 12, 2020 — New research confirms the high impact of PSMA PET/CT in the detection and management of recurrent disease in prostate cancer patients.

• Molecular Imaging Identifies Link between Heart and Kidney Inflammation after Heart Attack

  Jul 12, 2020 — Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction, or heart attack.

• Carolyn J. Anderson, PhD, Receives SNMMI 2020 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science

  Jul 12, 2020 — Carolyn J. Anderson, PhD, has been named the 2020 recipient of the prestigious Paul C. Aebersold Award. Anderson is a professor in the departments of medicine, radiology, bioengineering, chemistry, and pharmacology and chemical biology at the University of Pittsburgh in Pennsylvania.

• Stephen L. Bacharach, PhD, Receives SNMMI Georg Charles de Hevesy Nuclear Pioneer Award

  Jul 12, 2020 — Stephen L. Bacharach, PhD, a physicist known for his research in cardiac and PET oncology imaging, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.

• New PET Radiotracer Proven Safe and Effective in Imaging Malignant Brain Tumors

  Jul 12, 2020 — A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting has demonstrated the safety, favorable pharmacokinetic and dosimetry profile of 64Cu-EBRGD, a new, relatively long-lived PET tracer, in patients with glioblastomas.

• New PET/MRI Approach Pinpoints Chronic Pain Location, Alters Management

  Jul 11, 2020 — A new molecular imaging approach utilizing 18F-FDG positron emission tomography (PET) and magnetic resonance imaging can precisely identify the location of pain generators in chronic pain sufferers, often precipitating a new management plan for patients.

• Total-Body PET/CT Captures Full Picture of Systemic Inflammatory Arthritis

  Jul 11, 2020 — For the first time, physicians can examine the systemic burden of inflammatory arthritis simultaneously across all joints and organ systems, using the high-sensitivity, high-resolution uEXPLORER total-body positron emission tomography/computed tomography scanner

• Targeted Radionuclide Therapy Enhances Prostate Cancer Response to Immunotherapies

  Jul 11, 2020 — Targeted radionuclide therapy has been found to create a favorable tumor microenvironment in prostate cancer that improves the effectiveness of immunotherapies.

• Novel Radiotracer Measures Synaptic Activity After Stroke

  Jul 11, 2020 — A new radiotracer, 18F-SynVesT-2, can directly assess synaptic density changes in the brain, providing an objective and quantitative measure of disease progression after stroke.

• New Theranostic Agents Demonstrate Efficacy in Treatment of Prostate Cancer in Preclinical Studies

  Jul 11, 2020 — Researchers have developed a new pair of agents that show exceptional effectiveness for precision diagnosis and treatment of prostate cancer in preclinical studies.

• Journal of Nuclear Medicine Impact Factor Jumps More than Seven Percent

  Jun 29, 2020 — The Journal of Nuclear Medicine has achieved the highest impact factor ever in its 6o-year history, ranking fourth among all medical journals worldwide, according to new data just released in the 2019 Journal Citation Reports published by Clarivate Analytics.

• Technologists Answer Questions about COVID-19

  May 5, 2020 — The COVID-19 crisis has forced nuclear medicine departments to cancel appointments, change procedures and protocols and adapt rapidly to significant changes. To provide guidance to the community, SNMMI-TS interviewed eight nuclear medicine technologists from around the country.

• Announcement: SNMMI Annual Meeting

  Apr 30, 2020 — SNMMI President Vasken Dilsizian, MD, shares an important message unveiling the re-imagined SNMMI 2020 Annual Meeting—Virtual Edition.